Intrahepatic cholestasis in acute viral hepatitis: a double-blind trial with dihydroxydibutylether in comparison with placebo.
The authors studied the effectiveness of a choleretic drug, dihydroxydibutylether (DHBE), 900 mg daily, in patients with acute viral hepatitis and intrahepatic cholestasis. The four-week, double-blind and placebo-controlled trial showed a more rapid return to normal bilirubin and fasting and post-prandial biliary acid values and plasma transaminases levels in the DHBE-treated group of patients.